Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Summary

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

Timeline

Start

2022-03-24

Primary completion

2024-06-05

Completion

2024-06-05

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

Indications